Abbott Earns CE Mark for Mitral Regurgitation Therapy

Abbott has earned the CE Mark for its Tendyne transcatheter mitral valve implantation (TMVI) system, a treatment for significant mitral regurgitation.

Mitral regurgitation is a life-threatening condition where the heart’s mitral valve does not close completely, allowing blood to flow backwards into the heart’s left atrium.

The Tendyne system is an alternative for patients who are at high risk for open-heart surgery or who have mitral valves too damaged for repair, the company said.